JP2022517435A5 - - Google Patents
Info
- Publication number
- JP2022517435A5 JP2022517435A5 JP2021541712A JP2021541712A JP2022517435A5 JP 2022517435 A5 JP2022517435 A5 JP 2022517435A5 JP 2021541712 A JP2021541712 A JP 2021541712A JP 2021541712 A JP2021541712 A JP 2021541712A JP 2022517435 A5 JP2022517435 A5 JP 2022517435A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025027352A JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794450P | 2019-01-18 | 2019-01-18 | |
| US62/794,450 | 2019-01-18 | ||
| US201962821692P | 2019-03-21 | 2019-03-21 | |
| US62/821,692 | 2019-03-21 | ||
| US201962877044P | 2019-07-22 | 2019-07-22 | |
| US62/877,044 | 2019-07-22 | ||
| PCT/US2020/014296 WO2020150716A1 (en) | 2019-01-18 | 2020-01-20 | Treatment of diseases involving deficiency of enpp1 or enpp3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025027352A Division JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022517435A JP2022517435A (ja) | 2022-03-08 |
| JPWO2020150716A5 JPWO2020150716A5 (https=) | 2023-01-31 |
| JP2022517435A5 true JP2022517435A5 (https=) | 2023-01-31 |
| JP7724156B2 JP7724156B2 (ja) | 2025-08-15 |
Family
ID=71613451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541712A Active JP7724156B2 (ja) | 2019-01-18 | 2020-01-20 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
| JP2025027352A Pending JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025027352A Pending JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210187067A1 (https=) |
| EP (1) | EP3911153A4 (https=) |
| JP (2) | JP7724156B2 (https=) |
| KR (1) | KR20210142599A (https=) |
| CN (1) | CN113631033B (https=) |
| AU (1) | AU2020207967A1 (https=) |
| BR (1) | BR112021013941A2 (https=) |
| CA (1) | CA3126839A1 (https=) |
| IL (1) | IL284699A (https=) |
| MX (1) | MX2021008503A (https=) |
| WO (1) | WO2020150716A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022076848A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
| AU2021383830A1 (en) * | 2020-11-19 | 2023-06-22 | Biomarin Pharmaceutical Inc. | Treatment of enpp1 deficiency and abcc6 deficiency |
| WO2023049864A1 (en) * | 2021-09-24 | 2023-03-30 | Inozyme Pharma, Inc. | Lyophilized enpp1 polypeptide formulations and uses thereof |
| KR20240167914A (ko) * | 2022-04-04 | 2024-11-28 | 이노자임 파마, 인코포레이티드 | Enpp1 결핍증 및 abcc6 결핍증의 치료 |
| WO2025213139A1 (en) * | 2024-04-04 | 2025-10-09 | The General Hospital Corporation | Enpp1 gene therapy for the treatment of vascular disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6894022B1 (en) * | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| CA2462653C (en) * | 2001-11-07 | 2016-06-07 | Aya Jakobovits | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| EP1736553A1 (en) * | 2005-06-17 | 2006-12-27 | Centre National De La Recherche Scientifique | ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications |
| US8168586B1 (en) * | 2007-11-21 | 2012-05-01 | Celera Corporation | Cancer targets and uses thereof |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP3470089A1 (en) * | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| CA2960912A1 (en) * | 2014-09-16 | 2016-03-24 | Universitat Autonoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| EP3234116B1 (en) * | 2014-12-19 | 2021-09-08 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
| KR20250078598A (ko) * | 2015-05-19 | 2025-06-02 | 예일 유니버시티 | 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법 |
| BR112019002355A2 (pt) * | 2016-08-05 | 2019-07-16 | Yale University | composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme |
| EP3844280A4 (en) * | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
-
2020
- 2020-01-20 KR KR1020217025330A patent/KR20210142599A/ko not_active Ceased
- 2020-01-20 CA CA3126839A patent/CA3126839A1/en active Pending
- 2020-01-20 JP JP2021541712A patent/JP7724156B2/ja active Active
- 2020-01-20 WO PCT/US2020/014296 patent/WO2020150716A1/en not_active Ceased
- 2020-01-20 CN CN202080009084.9A patent/CN113631033B/zh active Active
- 2020-01-20 EP EP20741209.9A patent/EP3911153A4/en active Pending
- 2020-01-20 MX MX2021008503A patent/MX2021008503A/es unknown
- 2020-01-20 AU AU2020207967A patent/AU2020207967A1/en active Pending
- 2020-01-20 BR BR112021013941-9A patent/BR112021013941A2/pt unknown
-
2021
- 2021-02-17 US US17/178,127 patent/US20210187067A1/en not_active Abandoned
- 2021-07-08 IL IL284699A patent/IL284699A/en unknown
-
2022
- 2022-08-25 US US17/822,245 patent/US20230031809A1/en active Pending
-
2025
- 2025-02-21 JP JP2025027352A patent/JP2025084821A/ja active Pending